List of Excipients in Branded Drug KETOTIFEN FUMARATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rugby Laboratories	KETOTIFEN FUMARATE	ketotifen fumarate	0536-1252	BENZALKONIUM CHLORIDE
Rugby Laboratories	KETOTIFEN FUMARATE	ketotifen fumarate	0536-1252	GLYCERIN
Rugby Laboratories	KETOTIFEN FUMARATE	ketotifen fumarate	0536-1252	HYDROCHLORIC ACID

Generic Drugs Containing KETOTIFEN FUMARATE

Company	Ingredient	NDC	Excipient
KAISER FOUNDATION HOSPITALS	ketotifen fumarate	0179-8601	BENZALKONIUM CHLORIDE
KAISER FOUNDATION HOSPITALS	ketotifen fumarate	0179-8601	GLYCERIN
KAISER FOUNDATION HOSPITALS	ketotifen fumarate	0179-8601	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in KETOTIFEN FUMARATE?

# Of NDCs	Excipient
15	BENZALKONIUM CHLORIDE
15	GLYCERIN
15	HYDROCHLORIC ACID

Ketotifen Fumarate Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Ketotifen fumarate is a mature, low-cost small-molecule antihistamine and mast-cell stabilizer with established ophthalmic, oral, and selected investigational respiratory uses. The strongest commercial opportunities are differentiated delivery systems rather than new chemical-entity protection: preservative-free eye drops, contact-lens-compatible multidose systems, pediatric oral products, improved taste-masked solids, and combination or device-led products.

Patent barriers are generally weak because ketotifen has been marketed for decades. Regulatory execution, product convenience, tolerability, manufacturing reliability, and channel access are more important than composition-of-matter exclusivity.

What is ketotifen fumarate and where is it marketed?

Ketotifen fumarate is the fumarate salt of ketotifen, a piperidine-derived antihistamine with mast-cell-stabilizing activity. It is used primarily for allergic conjunctivitis and, outside the United States, in oral products for allergic disorders and asthma prophylaxis.

Attribute	Commercial profile
Active ingredient	Ketotifen fumarate
Pharmacology	H1-antihistamine and mast-cell stabilizer
Main dosage forms	Ophthalmic solution, oral tablet, oral syrup, oral granules in some markets
U.S. status	OTC ophthalmic allergy product; oral ketotifen is not a standard U.S. approved prescription product
Common ophthalmic strength	0.025% ketotifen equivalent, commonly supplied as approximately 0.035% ketotifen fumarate
Main competitors	Olopatadine, azelastine, cromolyn, pheniramine/naphazoline, oral antihistamines
Biosimilar relevance	None; ketotifen is a synthetic small molecule
Primary commercial issue	Differentiation in formulation, tolerability, convenience, and distribution

The U.S. OTC ophthalmic market includes ketotifen products such as Zaditor and Alaway. Their labeling identifies ketotifen fumarate as the active ingredient and positions the products for temporary relief of itchy eyes caused by pollen, ragweed, grass, animal hair, and dander [1,2].

What excipients are used in ketotifen fumarate ophthalmic products?

The conventional ophthalmic formulation is an aqueous, sterile solution. The excipient system must control pH, tonicity, microbial risk, ocular comfort, and chemical stability.

Typical commercial excipients include:

• Purified water as the vehicle.
• Glycerin as a tonicity-adjusting and comfort-enhancing agent.
• Benzalkonium chloride as a preservative in multidose products.
• Sodium hydroxide and hydrochloric acid for pH adjustment.
• Container-closure components designed for sterile ophthalmic delivery.

The Zaditor label identifies benzalkonium chloride at 0.01% and glycerin among the inactive ingredients [1]. Alaway labeling similarly identifies benzalkonium chloride and glycerin in its ophthalmic solution [2].

What is the role of benzalkonium chloride?

Benzalkonium chloride supports preservation in conventional multidose bottles but can create commercial limitations:

• Ocular-surface irritation with repeated use.
• Potential disruption of the tear film.
• Poor suitability for patients with dry eye or frequent dosing.
• Restrictions for contact-lens users, who generally must remove lenses before administration and wait before reinsertion.
• Competitive disadvantage against preservative-free allergy products.

A preservative-free ketotifen formulation could therefore command a premium if it maintains sterility, usability, shelf life, and acceptable manufacturing cost.

What is the role of glycerin?

Glycerin contributes to tonicity and may improve ocular comfort. It is inexpensive, widely accepted, and easy to scale. Its main commercial value is formulation robustness rather than differentiation. A developer should avoid unnecessary glycerin concentration increases because viscosity, drop size, osmolality, and patient sensation can change.

What formulation opportunities exist for ketotifen fumarate eye drops?

The most credible opportunities are preservative-free delivery, improved multidose packaging, contact-lens-compatible use, and reduced administration burden.

Preservative-free single-dose formulation

A unit-dose vial can remove benzalkonium chloride and reduce preservative-related tolerability concerns. The disadvantages are higher packaging cost, greater material consumption, more waste, and weaker convenience for frequent users.

Key excipient priorities are:

• Isotonicity without benzalkonium chloride.
• pH near the ocular comfort range.
• Low extractables and leachables.
• Low adsorption of ketotifen to polymer surfaces.
• Protection from oxidation and light if required.
• Adequate container integrity through shelf life.

Unit-dose packaging is most attractive for pediatric users, chronic allergy sufferers, dry-eye patients, and patients using several ophthalmic products.

Preservative-free multidose bottle

A preservative-free multidose system has greater commercial potential than a single-dose product because it combines improved tolerability with easier daily use. The formulation may remain chemically simple, but the container becomes a key part of the product.

Potential systems include:

• One-way valve bottles.
• Airless pump containers.
• Tip-protection systems.
• Filtered multidose dispensers.
• Metered-dose ophthalmic pumps.

The technical burden is higher. The sponsor must demonstrate microbial integrity after repeated opening and dosing, consistent delivered volume, compatibility with the formulation, and reliable priming across the product life cycle.

Viscosity-modified drops

A modest viscosity increase can prolong ocular residence time and reduce drainage. Candidates may include hydroxypropyl methylcellulose, hydroxypropyl cellulose, carbomers, polyvinyl alcohol, or povidone.

The commercial tradeoff is direct:

Benefit	Risk
Longer residence time	Blurred vision
Lower drainage	Stringiness or residue
Potentially less frequent dosing	Increased drop size or inconsistent delivery
Improved lubrication	More difficult sterilizing filtration or filling

A viscosity-enhanced ketotifen product should avoid a visibly gel-like profile. Allergy patients generally value rapid comfort and clear vision more than extended residence time.

Contact-lens-compatible formulation

Contact-lens users are a high-value segment because conventional preserved ophthalmic products often require lens removal. A product positioned for use with lenses would need careful evaluation of:

• Preservative and surfactant adsorption to lens materials.
• Drug uptake and release from lenses.
• Changes in lens transparency.
• Corneal exposure.
• Microbial safety.
• Labeling restrictions.

A true contact-lens-compatible ketotifen product could compete on convenience, but the claim would require clinical and compatibility evidence. It should not be inferred from preservative removal alone.

Improved pH and osmolality control

Ketotifen fumarate is a salt-form active, so pH adjustment can affect solubility, comfort, chemical stability, and preservative performance. A practical buffer strategy should use the lowest buffer capacity needed to control product pH. Excessive buffering can increase ocular discomfort and complicate compatibility with tears and other eye drops.

Potential buffering approaches include phosphate, citrate, borate, or low-capacity systems. Selection should be based on:

• Solubility across the shelf-life temperature range.
• Precipitation risk.
• Ocular tolerability.
• Container compatibility.
• Preservative efficacy.
• Sterilization and filling conditions.

What oral excipient strategies could support ketotifen fumarate?

Oral ketotifen products are established in several non-U.S. markets. The commercial opportunity is strongest in pediatric and adherence-focused formats.

Pediatric oral syrup

A syrup can address children who cannot swallow tablets. The formulation requires:

• Taste masking.
• Suspension or solution stability.
• Low microbial risk.
• Appropriate viscosity.
• Accurate dosing with an oral syringe.
• Sugar-free positioning where appropriate.

Ketotifen can cause drowsiness in some patients. A child-friendly product should therefore focus on dosing accuracy and tolerability rather than aggressive flavoring claims.

Potential excipient classes include glycerol, sorbitol, propylene glycol, hydroxyethylcellulose, xanthan gum, sodium benzoate or potassium sorbate where appropriate, citrate buffers, and flavor systems. Each requires evaluation for pediatric exposure, local regulatory limits, and interactions with the active salt.

Sugar-free oral liquid

A sugar-free formulation can target children, diabetic patients, and institutional channels. Polyols such as sorbitol can improve mouthfeel but may cause gastrointestinal effects at higher exposure. High-intensity sweeteners can reduce sugar load but may leave bitterness or aftertaste.

A commercial formulation should balance:

• Ketotifen bitterness.
• Sweetener intensity.
• Polyol burden.
• Viscosity.
• Preservative performance.
• Cost per dose.

Orally disintegrating tablet

An orally disintegrating tablet could improve convenience for pediatric or adult patients who have difficulty swallowing. The principal technical challenge is ketotifen taste. The formulation may require:

• Polymer or lipid taste-masking coatings.
• Ion-exchange resin complexes.
• Granulation with a barrier excipient.
• Rapid disintegration without premature drug release in the mouth.
• Low friability.
• Moisture-protective packaging.

Mannitol, crospovidone, croscarmellose sodium, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate are common platform excipients for this type of product, subject to compatibility and regulatory review.

Oral granules or sachets

Granules can support pediatric dosing and regional markets where sachet-based products are accepted. They also permit taste masking and flexible dose presentation. The main risks are dose uniformity, moisture sensitivity, powder handling, and reconstitution instructions.

What formulation patents protect ketotifen fumarate products?

The original ketotifen composition-of-matter and early product protection are historic. The practical U.S. opportunity is therefore generic or OTC product development, not a new chemical patent position.

Potentially relevant patent categories include:

1. Specific ophthalmic compositions.
2. Preservative-free sterile solutions.
3. Multidose dispensing systems.
4. Controlled-release oral dosage forms.
5. Taste-masked pediatric formulations.
6. Combination products with other allergy agents.
7. Nanoparticle, microemulsion, or in situ gel systems.
8. Manufacturing processes that improve impurity control or stability.

A later formulation patent may still create a narrow barrier even when the active ingredient is old. Its commercial value depends on claim scope, enforceability, prosecution history, remaining term, freedom-to-operate analysis, and whether a competing product can avoid the claims.

What is the Orange Book status of ketotifen fumarate?

The U.S. Orange Book is principally relevant to approved prescription drugs and their listed patents and exclusivity. OTC ketotifen ophthalmic products marketed under the applicable OTC framework do not present the same Orange Book listing structure as a newly approved prescription product.

The commercial consequences are material:

• A conventional OTC ketotifen product generally does not receive the same Hatch-Waxman exclusivity profile as a new prescription approval.
• Paragraph IV certification is relevant to an ANDA referencing an approved prescription drug with listed patents, not to ordinary OTC monograph competition.
• A sponsor seeking a new prescription product could create a different regulatory pathway, but that would require a separate approval basis and would not automatically establish broad market exclusivity.
• Device, formulation, or method-of-use patents may remain relevant even where the active ingredient has no meaningful remaining exclusivity.

FDA’s OTC monograph system and approved-drug databases should be reviewed separately from the Orange Book when analyzing ketotifen ophthalmic commercialization [3,4].

When does ketotifen fumarate lose exclusivity?

Ketotifen’s original active-ingredient exclusivity expired decades ago. No biosimilar pathway applies because ketotifen is a synthetic small molecule, not a biologic.

The current competitive structure is therefore:

Exclusivity type	Ketotifen position
Composition-of-matter patent	Historic and commercially expired
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current broad market effect identified
Orphan exclusivity	Not a central ketotifen market feature
Biosimilar exclusivity	Not applicable
OTC monograph protection	Limited compared with prescription exclusivity
Formulation patents	Possible for specific later-developed products
Device patents	Possible for dispensing systems
Method-of-use patents	Possible but generally narrow and use-specific

A launch strategy should treat ketotifen as an open active-ingredient market with potential product-level protection.

Which companies are challenging ketotifen fumarate products?

Competition is fragmented across branded OTC products, store brands, generic manufacturers, and non-ketotifen allergy products. The principal commercial competitors include:

• Generic and private-label ketotifen ophthalmic products.
• Zaditor and Alaway-branded products.
• Olopatadine ophthalmic products, including Pataday and generic versions.
• Azelastine ophthalmic products.
• Cromolyn ophthalmic products.
• Oral antihistamines used for broader allergy symptoms.

The strongest direct threat is olopatadine, which has a broad allergy brand presence and multiple OTC strengths and formulations. Ketotifen can compete through lower cost, established efficacy, preservative-free delivery, smaller packaging, pediatric usability, or pharmacy and private-label distribution.

What generic entry risks exist for ketotifen fumarate?

Generic entry risk is high for conventional ophthalmic products because the formulation is relatively simple and the active ingredient is mature. Key risk factors include:

• Low-cost active pharmaceutical ingredient supply.
• Established analytical methods.
• Familiar sterile filling processes.
• Limited active-ingredient exclusivity.
• Availability of standard ophthalmic excipients.
• Retail substitution and private-label competition.

The main barriers are operational rather than patent-based:

• Sterile manufacturing capacity.
• Container-closure qualification.
• Preservative efficacy.
• Extractables and leachables.
• Drop-size consistency.
• Stability in multidose packaging.
• FDA quality-system compliance.
• Retail listing and supply reliability.

A differentiated product can reduce direct price competition, but only if the benefit is visible to consumers, pharmacists, payers, or ophthalmology prescribers.

How strong is the ketotifen fumarate patent estate?

The base patent estate is weak because the molecule and conventional dosage forms are old. A new product could still build a moderate, narrow estate around formulation and delivery.

Stronger potential claim areas

• Preservative-free multidose delivery.
• Specific container and valve configurations.
• Stability-improving excipient combinations.
• Narrow pH and osmolality ranges tied to performance.
• Pediatric taste-masking systems.
• Controlled-release oral formulations.
• Combination products with defined ratios and dosing.
• Manufacturing processes that produce a distinctive impurity profile.

Weaker claim areas

• Broad claims to ketotifen fumarate in water.
• Routine use of glycerin or common buffers.
• Conventional benzalkonium chloride preservation.
• Generic claims to oral tablets or syrups.
• Broad claims covering allergy treatment without technical differentiation.

A patent strategy should pair composition claims with measurable performance claims. Examples include preservative reduction, improved multidose sterility, reduced drop volume, improved lens compatibility, or defined stability under accelerated conditions.

What licensing deals and commercial partnerships are relevant?

Ketotifen’s commercial history includes branded-product licensing and regional marketing arrangements, but the active ingredient is sufficiently mature that new value is more likely to arise from product, device, or distribution partnerships than from a license to the molecule itself.

Potential partnership models include:

• Contract development and manufacturing for sterile ophthalmic products.
• Licensing of preservative-free multidose containers.
• Regional OTC commercialization.
• Private-label pharmacy supply.
• Pediatric formulation licensing.
• Co-development with contact-lens or ocular-surface companies.
• Acquisition of a differentiated ophthalmic platform with ketotifen as an initial product.

The most valuable licensable asset would generally be a validated delivery platform that can also carry olopatadine, azelastine, cromolyn, or other ophthalmic actives.

What are the best commercial opportunities for ketotifen fumarate?

Opportunity	Commercial attractiveness	Main technical risk
Preservative-free single-dose drops	Medium	Packaging cost and waste
Preservative-free multidose drops	High	Sterility and container performance
Contact-lens-compatible product	Medium-high	Lens interaction and clinical substantiation
Low-cost private-label OTC drop	Medium	Price compression
Pediatric sugar-free syrup	Medium	Taste, stability, preservative system
Orally disintegrating tablet	Medium	Taste masking and moisture control
Sustained-release oral dosage form	Low-medium	Clinical value and regulatory burden
Ketotifen combination product	Medium	Differentiation and regulatory pathway
Novel nasal or pulmonary delivery	Low-medium	Clinical development and competition

The highest-probability program is a preservative-free ophthalmic product using a validated multidose container. The lowest-risk cost strategy is a conventional preserved solution for private-label or regional OTC distribution. Oral products can work in established international markets but face greater clinical and channel variability.

What regulatory milestones affect commercialization?

For a U.S. ophthalmic product, the regulatory pathway depends on whether the product fits the applicable OTC framework or requires an FDA application. A sponsor should expect scrutiny of:

• Active ingredient identity and strength.
• Sterility assurance.
• Product quality and impurity profile.
• Preservative efficacy where applicable.
• Container-closure integrity.
• Delivered dose and drop size.
• Stability.
• Labeling and consumer-use instructions.
• Manufacturing controls.

A new formulation that falls outside the established OTC framework may require an NDA or another FDA-supported regulatory route. A novel device may also require separate device-related assessment, depending on its design and claims [3,5].

Key Takeaways

• Ketotifen fumarate is a mature small molecule with no meaningful biosimilar issue and limited active-ingredient exclusivity.
• Conventional preserved ophthalmic solutions face high generic and private-label competition.
• Preservative-free multidose delivery is the strongest formulation opportunity.
• Contact-lens compatibility and improved ocular comfort can support premium positioning.
• Pediatric sugar-free liquids, orally disintegrating tablets, and granules are viable international opportunities.
• Patent value is likely to come from narrow formulation, packaging, manufacturing, or method-of-use claims.
• Commercial success depends more on sterile manufacturing, retail access, usability, and product differentiation than on molecule-level patent protection.
• A platform technology that can support multiple allergy actives has greater licensing value than ketotifen alone.

FAQs

Is ketotifen fumarate the same as ketotifen base?

No. Ketotifen fumarate is the salt form used in many finished products. Label strengths may be expressed as ketotifen equivalent rather than total ketotifen fumarate.

Can benzalkonium chloride be removed from a ketotifen eye-drop formulation?

Yes, but removal requires a different sterility and packaging strategy. A preservative-free product must maintain microbiological integrity through its intended use period.

Does ketotifen fumarate have biosimilar competition?

No. Ketotifen is a synthetic small molecule. Competition comes from generic drugs, OTC products, private-label products, and other allergy medicines.

Can ketotifen fumarate be used in a sustained-release oral product?

It can be formulated for modified release, but commercial value depends on demonstrating a meaningful benefit such as improved adherence, reduced peak-related adverse effects, or reduced dosing frequency.

What is the most defensible new patent position for ketotifen fumarate?

A narrow patent covering a validated preservative-free delivery system, specific stability-enhancing formulation, pediatric taste-masking system, or device-integrated product is more defensible than a broad claim to ketotifen fumarate in a conventional dosage form.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Zaditor ketotifen fumarate ophthalmic solution labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). DailyMed: Alaway ketotifen fumarate ophthalmic solution labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines

5. U.S. Food and Drug Administration. (2019). Guidance for industry: Container closure systems for packaging human drugs and biologics. https://www.fda.gov/ рег